A Multicentre Phase II trial of Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas
Trial Number
NCT04699071 (ClinicalTrials.gov Identifier)Contact Person
Status
Recruiting
Disease Site
Ovarian & Endometrial Primary
Lead Cooperative Group
Participating Groups
KGOG